CMS announces payment adjustments for EHR Incentive Program in FY2017

Hospitals that couldn’t show meaningful use of certified electronic health record (EHR) technology in their 2015 reporting will have their payments reduced by 75 percent in the next fiscal year, CMS announced.

The reduction would come from the hospital’s Inpatient Prospective Payment System (IPPS) rate. The adjustments have risen over the past several years, starting with a 25 percent decrease for FY2015 (for the 2013 reporting period) and then a 50 percent decrease for FY2016 (for the 2014 reporting period). The adjustment will stay at 75 percent past 2017.

The more than 4,800 hospitals eligible for the EHR Incentive Program can apply for a hardship exemption, based on factors like lack of broadband service or problems with their EHR vendor, but hospitals had to apply for an exemption by April 1.

Most hospitals won’t need an exemption or a payment adjustment, as CMS said 98 percent of eligible hospitals and critical access hospitals successfully demonstrated meaningful use “at either Stage 1 or Stage 2,” leaving around 100 hospitals who failed to meet those standards.

The agency’s fact sheet pointed out hospitals have to demonstrate meaningful every year to avoid reductions to payments.

“For example, an eligible hospital that demonstrates meaningful use for the first time in 2013 will avoid the payment adjustment in FY2015, but will need to demonstrate meaningful use again in 2015 in order to avoid the payment adjustment in FY2017,” CMS said. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.